CLOUD – Closed Loop from Onset in type 1 Diabetes

Recruitment closed

Recruiting sites

  • Cambridge University Hospitals NHS Foundation Trust
  • Alder Hey Children’s NHS Foundation Trust
  • Nottingham Children’s Hospital
  • Oxford Children’s Hospital
  • Southampton Childrens Hospital
  • Royal Hospital for Sick Children, Edinburgh


CLOuD is a multicentre, randomised trial of an exciting new artificial pancreas device, in newly diagnosed adolescents with type 1 diabetes (T1D) funded by the EME Programme (an MRC and NIHR partnership) and the Helmsley Charitable Trust. The artificial pancreas is designed to mimic the normal healthy activity of beta-islet pancreatic cells in response to blood glucose levels. The device is a closed loop system combining real time continuous glucose monitoring with insulin pump therapy and a computer-based algorithm to calculate the amount of insulin required to keep blood glucose levels within target range. The aim is to prolong residual insulin secretion after T1D diagnosis, via intensive metabolic control using the artificial pancreas closed loop system, in order to minimise long-term complications and reduce the risk of hypoglycaemia. This is the first trial of its kind analysing the use of the artificial pancreas in newly diagnosed T1D patients.

96 participants aged 10 to 16 will be recruited within 10 working days of diagnosis of Type 1 Diabetes from 5 UK sites and will be randomised 1:1 to either closed loop or standard therapy (Multiple Daily Injections). Participants will have study visits and assessments every 3 months for a total of 24 months.